Alcohol addiction: Toward a patient-oriented pharmacological treatment

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 16, 2013, Pages 2157-2160

  Addolorato, Giovanni ^a   Mirijello, Antonio ^a   Leggio, Lorenzo ^b,c,d  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Alcohol use disorder; Drug treatment

Indexed keywords

ACAMPROSATE; BACLOFEN; DISULFIRAM; NALTREXONE;

ALCOHOL ABSTINENCE; ALCOHOL LIVER DISEASE; ALCOHOL USE DISORDER; ALCOHOLISM; CLINICAL PRACTICE; COMORBIDITY; CRITICALLY ILL PATIENT; EDITORIAL; FATTY LIVER; HEALTH CARE PERSONNEL; HUMAN; LIVER FIBROSIS; LIVER FUNCTION TEST; MEDICAL SCHOOL; PREDICTIVE VALUE; TREATMENT OUTCOME;

ALCOHOL DETERRENTS; ALCOHOLISM; HUMANS;

EID: 84885606500     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.834047     Document Type: Editorial

References (14)

1. Del Re AC, Maisel NC, Blodgett J, Finney J. The declining efficacy of Naltrexone pharmacotherapy for alcohol use disorders over time: a multivariate meta-analysis. Alcohol Clin Exp Res 2013;37:1064-8
2. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003;28:1546-52 (Pubitemid 41070891)
3. Anton RF, Oroszi G, O'Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study. Arch Gen Psychiatry 2008;65:135-44 (Pubitemid 351222547)
4. Kiefer F, Witt SH, Frank J, et al. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 2011;11:368-74
5. Kiefer F, Helwig H, Tarnaske T, et al. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res 2005;11:83-91 (Pubitemid 40529262)
6. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000;284:963-71 (Pubitemid 30659126)
7. Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 2011;168:265-75
8. Kenna GA, Zywiak WH, McGeary JE, et al. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcoholdependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res 2009;33:315-23
9. Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des 2010;16:2113-17
10. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007;370:1915-22 (Pubitemid 350192657)
11. Garbutt JC, Kampov-Polevoy AB, Gallop R, et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010;34:1849-57
12. Leggio L, Zywiak WH, McGeary JE, et al. A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacol Biochem Behav 2013;103:784-91
13. Addolorato G, Mirijello A, Leggio L, et al. Management of alcohol dependence in patients with liver disease. CNS Drugs 2013;27:287-99
14. Leggio L, Ferrulli A, Zambon A, et al. Baclofen promotes alcohol abstinence in alcohol-dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav 2012;37:561-4